You Position: Home > Paper
The clinical effect of Huaier granule combined with chemotherapy in postoperative adjuvant treat-ment of cholangiocarcinoma
( views:235, downloads:44 )
- Author:
- No author available
- Journal Title:
- China Clinical Practical Medicine
- Issue:
- 2
- DOI:
- 10.3760/cma.j.issn.1673-8799.2018.02.003
- Key Word:
- 槐耳颗粒;胆管癌;辅助治疗
Abstract： 目的 探讨槐耳颗粒联合化学治疗对胆管腺癌术后患者的不良反应发生率、生活质量及生存期的影响.方法 回顾性分析2015年6月至2017年6月解放军沈阳军区总医院肿瘤科收治的50例胆管腺癌根治术后辅助化学治疗患者的临床资料,按照是否联合应用槐耳颗粒分为基础治疗组与槐耳颗粒治疗组.基础治疗组22例患者,术后应用XELOX方案,共治疗6个周期.槐耳颗粒治疗组28例患者,在XELOX方案化学治疗基础上同时口服槐耳颗粒6周.记录并比较两组患者的不良反应发生率、生活质量改善情况及无进展生存期.结果 槐耳颗粒治疗组患者的白细胞减少发生率、恶心发生率低于基础治疗组,差异有统计学意义(P<0.05);槐耳颗粒治疗组血小板下降发生率、肝损害发生率高于基础治疗组,差异无统计学意义(P>0.05).槐耳颗粒治疗组患者生活质量的总改善率(60.7％)高于基础治疗组(31.8％),差异有统计学意义(P<0.05).槐耳颗粒治疗组患者的无进展生存期较基础治疗组显著延长.结论 槐耳颗粒联合化学治疗可以降低胆管腺癌术后辅助化学治疗患者的白细胞减少及恶心发生率,改善其生活质量,延长其生存期.
- [1]陈大兴,陈孝平,张万广.槐耳清膏治疗肝癌的实验研究[J].2004,(8).
- [2]韩大力,王克山,于甬华.胆管癌的诊断与治疗研究进展[J].2013,(42).
- [3]李思维,邹立勇,尹宜发.槐耳颗粒在肿瘤临床中的应用[J].2005,(10).
- [4]韩月婷,邓婷,潘虹,等.RRM1对胆道系统恶性肿瘤患者术后辅助化疗疗效的预测价值[J].2016,(41).
- [5]徐玲,赵玉亮.胆管癌及其治疗现状[J].2007,(5).
- [6]钱军,张立功,贾建光,等.槐耳颗粒联合FOLFOX4方案治疗结直肠癌的临床观察[J].2012,(4).
- [7]王晓庆,张晟,张瑾.槐耳清膏对乳腺癌患者外周血单核细胞分泌细胞因子的影响[J].2011,(5).
- [8]Sasaki M,Nakanuma Y,Terada T,etc.Biliary epithelial expression of MUC1, MUC2, MUC3 and MUC5/6 apomucins during intrahepatic bile duct development and maturation. An immunohistochemical study.[J].1995,147(3).
- [9]Al Kawas FH,Charbel H.Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.[J].2011,13(2).
- [10]Sopit Wongkham,John Kieran Sheehan,Chanchai Boonla,etc.Serum MUC5AC mucin as a potential marker for cholangiocarcinoma[J].2003,195(1).
- [11]Chen, Yang,Wu, Huan,Wang, Xinheng,etc.Huaier Granule extract inhibit the proliferation and metastasis of lung cancer cells through down-regulation of MTDH, JAK2/STAT3 and MAPK signaling pathways[J].2018,101.
- [12]Zhu AX,Hezel AF.Systemic therapy for biliary tract cancers.[J].2008,13(4).
- [13]Broome U,Bergquist A,Thorne A,etc.Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis.[J].2002,34(11).
- [14]Morris DL,Sarkar A,Chu F,etc.Clinicopathologic and treatment-related factors influencing recurrence and survival after hepatic resection of intrahepatic cholangiocarcinoma: a 19-year experience from an established Australian hepatobiliary unit.[J].2010,14(7).
- [15]Ding H,Li C,Huang B,etc.Value of contrast-enhanced sonography in the diagnosis of peripheral intrahepatic cholangiocarcinoma.[J].2011,39(8).
- [16]Hu, Zhongdong,Yang, Ailin,Fan, Haitao,etc.Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling[J].2016,186.
- [17]李勤裕,吴卫泽,韩天权,等.胆管癌的分子靶向治疗[J].2012,(14).
- [18]Kysela P,Kala Z,Valek V,etc.Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: A prospective randomised study.[J].2007,62(2).
- [19].Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J].2014,60(6).
- [20]Alvaro D,Gatto M.Cholangiocarcinoma: risk factors and clinical presentation.[J].2010,14(4).
- [21]Shinohara, E. T.,Mitra, N.,Guo, M.,etc.Radiation Therapy Is Associated With Improved Survival in the Adjuvant and Definitive Treatment of Intrahepatic Cholangiocarcinoma[J].2008,72(5).